Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions ...

Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...

The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products ...

The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and ...

Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched ...

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now ...

Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of ...